{"id":"W3030729340","doi":"10.1200/jco.2020.38.15_suppl.6010","title":"A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Oncology; Cabozantinib; Progression-free survival; Endometrial cancer; Urology; Cancer; Surgery; Gastroenterology; Immunotherapy; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002168032,0.001709502,0.003039449,0.0004857544,0.0003931861,0.0009948313,0.000925019,0.001972277,0.009703706],"category_scores_gemma":[0.002058452,0.001136993,0.001466024,0.0004202141,0.0010807,0.0009573359,0.0004637718,0.002636028,0.001920363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001039776,"about_ca_system_score_gemma":0.001829674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001111328,"about_ca_topic_score_gemma":0.003282891,"domain_scores_codex":[0.9991842,0.0004886594,0.00004357168,0.0001255097,0.00004916428,0.0001088726],"domain_scores_gemma":[0.9989747,0.0002552747,0.0002361488,0.00009151924,0.00006280931,0.0003796718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733275,0.008811366,0.0004528186,0.0003717586,0.0004799747,0.00003444791,0.00004001352,0.0002875799,0.003167133,0.00007216074,0.000835532,0.01211983],"study_design_scores_gemma":[0.940431,0.05758166,0.0006862596,0.000015402,0.0001851464,0.0000255404,0.00001106412,0.0002231891,0.0001565923,0.00009407142,0.0005825873,0.000007523321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699717,0.006595617,0.001058827,0.001133673,0.001027665,0.01430608,0.002087127,0.0002070425,0.003612234],"genre_scores_gemma":[0.9653562,0.003921464,0.003137975,0.00274553,0.0006825175,0.01614649,0.001985428,0.00005301431,0.005971281],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009703706,"threshold_uncertainty_score":0.03246212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1661395798558401,"score_gpt":0.4908497602442609,"score_spread":0.3247101803884208,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}